Paying users zone. Data is covered by hidden.

  • Get to Biogen Inc. for $15.99, or

  • get to whole website for at least 3 months from $49.99.

Microsoft Excel LibreOffice Calc


Common Stock Valuation Ratios (Price Multiples)

Difficulty: Beginner


Current Valuation Ratios

Biogen Inc., current price multiples

Microsoft Excel LibreOffice Calc
Biogen Inc. Abbott Laboratories AbbVie Inc. Allergan PLC Amgen Inc. Bristol-Myers Squibb Co. Celgene Corp. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Pharmaceuticals & Biotechnology Health Care
Selected Financial Data
Current share price (P) $ hidden
No. shares of common stock outstanding hidden
Growth rate (g) hidden
 
Earnings per share (EPS) $ hidden
Next year expected EPS $ hidden
Operating profit per share $ hidden
Sales per share $ hidden
Book value per share (BVPS) $ hidden
Ratios (Price Multiples)
Price to earnings (P/E) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Price to next year expected earnings hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Price-earnings-growth (PEG) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Price to operating profit (P/OP) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Price to sales (P/S) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Price to book value (P/BV) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-01).

If company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.

Otherwise, if company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

Biogen Inc., historical price multiples

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Price to earnings (P/E) hidden hidden hidden hidden hidden
Price to operating profit (P/OP) hidden hidden hidden hidden hidden
Price to sales (P/S) hidden hidden hidden hidden hidden
Price to book value (P/BV) hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04), 10-K (filing date: 2014-02-06).

Ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Biogen Inc.'s P/E ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Biogen Inc.'s P/OP ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Biogen Inc.'s P/S ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company's required rate of return and its actual rate of return. Biogen Inc.'s P/BV ratio declined from 2015 to 2016 but then increased from 2016 to 2017 not reaching 2015 level.

Price to Earnings (P/E)

Biogen Inc., historical P/E calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1 hidden hidden hidden hidden hidden
Selected Financial Data (USD $)
Net income attributable to Biogen Inc. (in thousands) hidden hidden hidden hidden hidden
Earnings per share (EPS)3 hidden hidden hidden hidden hidden
Share price1, 2 hidden hidden hidden hidden hidden
Ratio
P/E ratio4 hidden hidden hidden hidden hidden
Benchmarks
P/E Ratio, Competitors
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
P/E Ratio, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
P/E Ratio, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04), 10-K (filing date: 2014-02-06).

1 Data adjusted for splits and stock dividends.

2 Close price on the filing date of Biogen Inc.'s Annual Report.

2017 Calculations

3 EPS = Net income attributable to Biogen Inc. ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

4 P/E ratio = Share price ÷ EPS
= hidden ÷ hidden = hidden

Ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Biogen Inc.'s P/E ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.

Price to Operating Profit (P/OP)

Biogen Inc., historical P/OP calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1 hidden hidden hidden hidden hidden
Selected Financial Data (USD $)
Income from operations (in thousands) hidden hidden hidden hidden hidden
Operating profit per share3 hidden hidden hidden hidden hidden
Share price1, 2 hidden hidden hidden hidden hidden
Ratio
P/OP ratio4 hidden hidden hidden hidden hidden
Benchmarks
P/OP Ratio, Competitors
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
P/OP Ratio, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
P/OP Ratio, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04), 10-K (filing date: 2014-02-06).

1 Data adjusted for splits and stock dividends.

2 Close price on the filing date of Biogen Inc.'s Annual Report.

2017 Calculations

3 Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

4 P/OP ratio = Share price ÷ Operating profit per share
= hidden ÷ hidden = hidden

Ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Biogen Inc.'s P/OP ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.

Price to Sales (P/S)

Biogen Inc., historical P/S calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1 hidden hidden hidden hidden hidden
Selected Financial Data (USD $)
Revenues (in thousands) hidden hidden hidden hidden hidden
Sales per share3 hidden hidden hidden hidden hidden
Share price1, 2 hidden hidden hidden hidden hidden
Ratio
P/S ratio4 hidden hidden hidden hidden hidden
Benchmarks
P/S Ratio, Competitors
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
P/S Ratio, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
P/S Ratio, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04), 10-K (filing date: 2014-02-06).

1 Data adjusted for splits and stock dividends.

2 Close price on the filing date of Biogen Inc.'s Annual Report.

2017 Calculations

3 Sales per share = Revenues ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

4 P/S ratio = Share price ÷ Sales per share
= hidden ÷ hidden = hidden

Ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Biogen Inc.'s P/S ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.

Price to Book Value (P/BV)

Biogen Inc., historical P/BV calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1 hidden hidden hidden hidden hidden
Selected Financial Data (USD $)
Total Biogen Inc. shareholders' equity (in thousands) hidden hidden hidden hidden hidden
Book value per share (BVPS)3 hidden hidden hidden hidden hidden
Share price1, 2 hidden hidden hidden hidden hidden
Ratio
P/BV ratio4 hidden hidden hidden hidden hidden
Benchmarks
P/BV Ratio, Competitors
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
P/BV Ratio, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
P/BV Ratio, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04), 10-K (filing date: 2014-02-06).

1 Data adjusted for splits and stock dividends.

2 Close price on the filing date of Biogen Inc.'s Annual Report.

2017 Calculations

3 BVPS = Total Biogen Inc. shareholders' equity ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

4 P/BV ratio = Share price ÷ BVPS
= hidden ÷ hidden = hidden

Ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company's required rate of return and its actual rate of return. Biogen Inc.'s P/BV ratio declined from 2015 to 2016 but then increased from 2016 to 2017 not reaching 2015 level.